中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 差异化分红事项的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为上海微 创心脉医疗科技（集团）股份有限公司（以下简称"公司"、"心脉医疗"）向特定对 象发行股票项目的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号——回购股 份》等相关法律法规和规范性文件的要求，对心脉医疗2024年年度利润分配涉及的差异 化分红事项（以下简称"本次差异化分红"）进行了审慎核查，具体情况如下： 一、本次差异化分红的原因 2024 年 7 月 23 日，公司召开第二届董事会第二十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证券交易 所系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，并在未 来适宜时机全部用于股权激励或员工持股计划。公司本次回购价格不超过人民币 130.00 元/股（含），回购资金总额不低于人民币 6,000.00 万元（含），不超过人民币 10,000.00 ...

公司拟以实施 2024 年年度权益分派股权登记日的总股本（扣减回购专用证 券账户的股份）为基数，向全体股东每 10 股派发现金红利人民币 3.5 元（含税）。 截至 2025 年 2 月 28 日，公司总股本为 123,262,117 股，其中，公司回购证券专 用账户的股份数量为 1,952,089 股，以此扣减回购专用账户的股份数量后公司股 现金分红总额调整情况：维持每10股派发现金红利3.5元（含税）不变， 现金分红总额由42,458,509.80元（含税）调整为42,444,159.80元（含税）。 调整原因：自2025年3月1日起至本公告披露日，公司通过上海证券交易 所交易系统以集中竞价交易方式回购公司股份41,000股。因公司回购专 用证券账户中股份总数发生变动，实际参与本次利润分配的股份总数调 整为121,269,028股。根据公司2024年度利润分配方案，维持应分配每股 比例不变，相应调整分配总额。 份数量为 121,310,028 股，以此计算公司拟派发现金红利总额为 42,458,509.80 元 （含税）。公司不进行资本公积金转增股本，不送红股。 如在利润分配预案披露 日至实施权益分派股权 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-025 上海微创心脉医疗科技（集团）股份有限公司 关于实施 2024 年度利润分配方案后调整第二期股份 回购方案回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 回购股份的基本情况 2024 年 10 月 28 日，上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）召开第三届董事会第二次会议，审议通过了《关于以集中竞价交 易方式第二期回购公司股份方案的议案》,同意公司以自有资金和/或自筹资金通 过上海证券交易所系统以集中竞价交易方式回购公司已发行的部分人民币普通 股（A 股）股票，并在未来适宜时机全部用于股权激励或员工持股计划。公司本 次回购价格不超过人民币 180 元/股（含），回购资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的实施期限自董事会审 议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2024 年 10 月 30 日刊登在上海证券交易 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-023 上海微创心脉医疗科技（集团）股份有限公司 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 18 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.35元 相关日期 1. 发放年度：2024年年度 2. 分派对象： 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/5 | 2025/6/6 | 2025/6/6 | （1）差异化分红方案 根据公司 2024 年 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 2.05% increase over the past month but a 3.91% decrease over the past three months, and a year-to-date decline of 0.28% [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.71%), United Imaging (10.72%), Aibo Medical (6.92%), Yirui Technology (6.59%), Nanwei Medical (5.3%), Shengxiang Biology (4.93%), Xinmai Medical (4.6%), Haier Biomedical (4.24%), Yahui Long (3.64%), and Aohua Endoscopy (3.34%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - The industry composition of the index holdings includes 45.64% in medical consumables, 33.41% in medical devices, and 20.95% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

Core Viewpoint - Shanghai MicroPort Cardiac Interventional Medical Technology (Group) Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating potential challenges in the company's financial performance and operational efficiency [2][6]. Financial Performance - The company's revenue for Q1 2025 was 332 million yuan, a year-on-year decrease of 7.23% [6]. - The net profit attributable to shareholders was 130 million yuan, down 29.66% year-on-year; the net profit excluding non-recurring items was 122 million yuan, a decline of 31.27% [6]. - Gross margin was 69.61%, down 6.90% year-on-year, while net margin was 38.53%, a decrease of 12.54% [6]. - Basic earnings per share were 1.05 yuan [6]. Expense Analysis - Total operating expenses (selling, administrative, and financial expenses) amounted to 63.01 million yuan, increasing from 9.72% to 18.97% of total revenue, a growth of 95.05% [7]. - Selling expenses rose by 68.09%, administrative expenses increased by 60.62%, while R&D expenses decreased by 31.26% and financial expenses grew by 56.24% [7]. Asset Status - As of the end of the reporting period, the company's cash and cash equivalents were 1.086 billion yuan, a decrease of 26.32% year-on-year [8]. - Accounts receivable stood at 355 million yuan, an increase of 83.78% year-on-year [8]. - Interest-bearing liabilities reached 152 million yuan, a significant increase of 1217.07% year-on-year [8]. Business Development - The company has made progress in the active artery intervention field, with several products receiving regulatory approvals and entering clinical trials [11][16]. - Key products include the Cratos® branched aortic stent system and Hector® thoracic aortic multi-branch stent system, both of which have received domestic approval [11]. - The company has subsidiaries focused on various interventional fields, enhancing its market presence and product offerings [15].

Summary of Heart Medical's Conference Call Company Overview - **Company**: Heart Medical - **Industry**: Medical Devices, specifically focusing on interventional cardiology and oncology Key Financial Performance - **Q1 2025 Net Profit**: Decreased by 31.27% to 122 million yuan, impacted by market environment changes and product strategy adjustments [2][4] - **Q1 2025 Revenue**: 332 million yuan, down 7.23% year-on-year [4] - **International Revenue Growth**: Increased by over 93%, now accounting for more than 16% of total revenue [2][10] - **R&D Investment**: 29 million yuan, representing 8.75% of revenue, slightly down from the previous year [5] Product Development and Innovations - **Active Aortic Intervention**: - Creatus branched stent launched - AKE multi-branch stent in green channel for approval - ARB abdominal aortic stent completed clinical implantation [2][6][7] - **Peripheral Vascular Intervention**: - Submissions for registration of various products, including a detachable fiber embolization coil and drug balloon dilatation catheter [2][8] - **Oncology Intervention**: - Intravenous liver puncture kit approved, with ongoing development of 3D balloons and TIPS stents [2][9] Market Expansion and Strategy - **Global Strategy**: - Accelerating overseas expansion with 15 products undergoing CE certification [3][10] - Products now in over 2,500 domestic hospitals and 40+ countries internationally [10] - **Impact of Tariffs**: - Chinese tariffs on imports may affect inventory levels but are not expected to significantly hinder domestic market growth [11] Sales and Distribution Channels - **Distributor Stability**: - Overall distributor team remains stable with new agents joining, particularly in county-level hospitals [14] - **Inventory Levels**: - Maintained at approximately 4 months, with no significant changes expected [13][14] Regulatory and Competitive Landscape - **Collective Procurement Impact**: - Ongoing discussions with the National Medical Insurance Bureau regarding the timing of collective procurement in Hebei, which may affect supply in the short term [13] - **Market Competition**: - Focus on enhancing competitiveness through product innovation and strategic partnerships, especially in the face of price pressures from collective procurement [17][24] Future Outlook - **Revenue Projections**: - Anticipated growth in overseas revenue, aiming for 15-20% in 2025, with a long-term goal of exceeding 30% [18] - **Product Pipeline**: - Continued focus on expanding the product line and enhancing market penetration, particularly in the peripheral vascular segment [24][32] Additional Insights - **Cash Flow Management**: - Low operating cash flow attributed to investment strategies and the need for improved financial management [25] - **Accounts Receivable**: - Increase due to new product promotions and market expansion into county-level hospitals [26][27] - **County Market Development**: - Focus on expanding product offerings in county markets, leveraging existing channels to promote aortic products [28] This summary encapsulates the key points from Heart Medical's conference call, highlighting financial performance, product development, market strategies, and future outlook.

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.40% increase over the past month and a 0.19% increase over the past three months, while it has decreased by 0.01% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.76%), United Imaging (10.54%), Aibo Medical (7.72%), Yirui Technology (6.34%), Shengxiang Biology (5.03%), Nanwei Medical (5.02%), Xinmai Medical (4.57%), Haier Biomedical (4.39%), Yahui Long (3.59%), and Aohua Endoscopy (3.38%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - The industry composition of the index holdings includes 46.02% in medical consumables, 33.17% in medical devices, and 20.81% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which are fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be processed according to the calculation and maintenance guidelines [2]

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23% [2] - The net profit for the same period was 130 million yuan, down 29.66% year-on-year, with a gross profit margin of 69.61% [2] Market Position - As of May 6, the company's stock closed at 86.03 yuan, with a PE ratio of 23.70 times, and a total market capitalization of 10.604 billion yuan [1] - The average PE ratio in the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 52nd position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders reached 18,176, an increase of 523 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]